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Antiviral activity of an interferon-inducing mycoviral ds RNA against Semliki Forest virus infection was 
considerably enhanced by N-palmitoylmuramyl-L-alanyl-D-isoglutamine (PMDP), a new muramyl dipep- 
tide. This enhancement in activity was not due to increased production of interferon, but resulted probably 
from a PMDP-induced increase in nonspecific resistance to infection. These results indicate that a combined 
treatment with an interferon inducer and muramyl dipeptide may prove highly useful to control effectively 
viral infections. 
Viral infection Interferon inducer Muramyi dipeptide Macrophage activation 
1. INTRODUCTION 
MDP and its derivatives stimulate humoral and 
cell-mediated immune responses to various an- 
tigens f1,2] and are known to enhance nonspecific 
resistance to bacterial, fungal and protozoal 
pathogens [3-51. In addition, treatment of mice 
with liposomes containing muramyl tripeptide has 
been shown to confer protection against herpes 
simplex type 2 infection [6]. Here we demonstrate 
that the antiviral activity of an interferon-inducing 
mycoviral ds RNA is considerably enhanced if the 
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animals are also treated with PMDP (a new MDP 
derivative). We further show that this enhance- 
ment in activity is not due to increased production 
of interferon, but probably results from a PMDP- 
induced increase in nonspecific resistance to 
infection. 
2. MATERIALS AND METHODS 
2.1. Animals 
Randomly bred Swiss mice weighing 14-15 g 
were used in all experiments. All the animals had 
access to food (pellet diet, Hindustan Lever, Bom- 
bay) and water ad libitum. Each experimental 
group consisted of an equal number of male and 
female animals. 
2.2. Virus 
SFV (Smithburn and Haddow strain) originally 
obtained from the American Type Culture Collec- 
tion was maintained in our laboratory by in- 
tracerebral passage in mice. A 20% homogenate of 
the infected mouse brain in PBS containing 0.1% 
bovine serum albumin was lyophilized and stored 
at -20°C. The stock virus was titrated before use 
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by subcutaneous inoculation in mice, and LDsc 
was calculated using the formula of Reed and 
Muench [7]. VSV was obtained from the National 
Institute of Virology, Pune (India) and stored at 
- 50°C. The virus was titrated in LM cells to 
calculate 50% tissue culture infective dose. 
2.3. Mycoviral ds RNA 
Mycoviral ds RNA was prepared from 9-day-old 
stationary cultures of the fungus Aspergillus 
ochraceus ATCC 28706, as described in [8]. 
2.4. Muramyl dipeptides 
MDP was prepared as in [9]. PMDP was syn- 
thesized by conventional methods, and character- 
ized by FAB/FD mass spectrometry (unpub- 
lished). 
2.5. Animal experiments 
Unless mentioned otherwise, ds RNA 
(0.6 mg/kg) and PMDP (in 0.5 ml PBS) were ad- 
ministered intraperitoneally to mice. The animals 
were challenged with SFV subcutaneously, and 
observed for a period of 20 days to record symp- 
toms and mortality. The day of challenge is re- 
ferred to as day 0 while other days are referred to 
as minus or plus (before and after the challenge, 
respectively) to indicate the days of treatment. The 
significance @ value) of the various treatment 
schedules was calculated by the test of proportions 
[lOI. 
2.6. Interferon assay 
Mice treated with ds RNA, PMDP or ds RNA 
plus PMDP were bled at various time intervals, 
and the serum separated and assayed for in- 
terferon. Interferon assay was carried out by the 
plaque reduction method on LM cell monolayers 
using VSV as the challenge virus. Reference mouse 
interferon procured from the National Institute of 
Health, USA (WHO international reference 
preparation, cat. no. G-002-904-5 11) was used as a 
standard for comparison, and to facilitate expres- 
sion of interferon titre in IU/ml. 
3. RESULTS AND DISCUSSION 
Recovery from viral infections is a complex pro- 
cess, and depends mainly upon the interplay of 
host defence mechanisms including the interferon 
38 
and immune responses [111. In appropriate cases 
interferon is produced in the blood stream within 
hours of virus inoculation or during viraemia and 
is distributed in target organs, conferring cellular 
resistance against further spread of virus [12] 
followed by antibody response which starts later 
during infection. The harmonious action of both 
interferon and immune responses may be necessary 
for the host to recover from the lethal infection 
[13]. We have observed that mice infected with 
SFV show paralytic symptoms from day + 4 on- 
wards and all succumb to infection by day + 9. If 
the animals were treated with an interferon in- 
ducer, a mycoviral ds RNA, 1 day before or just 
prior to challenge, about 60-70% recover from the 
infection. The mice that do not recover despite the 
ds RNA treatment (30-40%) develop symptoms 
and ultimately die between day + 9 and + 20. 
These animals were found to have interferon levels 
Table 1 
Effect of PMDP treatment on the anti SFV activity of 
ds RNA 
Expt Treatment PDMP N Protec- p 
dose tion 
(m&kg) (%o) 
I PBS - 10 0 - 
ds RNA - 10 60 - 
ds RNA + 
PMDP 0.6 10 50 - 
ds RNA + 
PMDP 1.5 10 60 - 
ds RNA + 
PMDP 3.0 10 80 - 
ds RNA + 
PMDP 6.0 10 100 <O.l 
ds RNA + 
PMDP 15.0 10 100 <O.l 
ds RNA + 
PMDP 30.0 10 90 - 
II PBS - 30 0 - 
ds RNA - 30 53 - 
ds RNA + 
PMDP 6.0 30 90 CO.01 
ds RNA was administered on day - 1 while PMDP was 
given on day 0. Animals were challenged with 100 LD~,, 
of virus, and observed for a period of 20 days to record 
occurrence of paralysis and death. N, number of mice 
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similar to those which survived the infection (un- 
published), suggesting that the interferon response 
alone may not be sufficient for effective protection 
against SFV infection. It was therefore considered 
appropriate to examine the effect of muramyl 
dipeptides on the antiviral activity of ds RNA, as 
these glycopeptides are known to possess strong 
immunomodulatory activity [ 1,2]. 
Table 1 shows that the mice treated with ds RNA 
24 h before challenge with 100 LDSO of SFV were 
protected against infection to an extent of 55-609’0 
only. This protection was considerably enhanced 
(!I@-100%) upon administering a single dose of 
PMDP to the ds RNA-treated animals on day 0. 
The optimal dose of PMDP required to obtain the 
maximum effect was about 6 mg/kg. A similar 
treatment with MDP (6 mg/kg) or with several 
other MDP derivatives (not shown) did not 
100 
 ^ 80 
2 . 
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F&l. Effects of viral dose (A) [PMDP (6 mg/kg) was 
given on day 0] and the day of PMDP administration (B) 
(The doses of virus and PMDP were 100 LDso and 
6 mg/kg, respectively. No animal in the control group 
survived up to day + 20.) on SFV infection in ds RNA- 
treated mice. Bars: solid, control mice given 0.5 ml PBS 
only; shaded, ds RNA-treated mice; open, ds RNA plus 
PMDP-treated mice. Each group consisted of 15-20 
animals. ds RNA was given on day - 1. was given 4 h before ds RNA administration. 
Fig.2. Interferon titres in serum of mice that were given 
ds RNA (H), PMDP (6 mg/kg: x---x) or ds RNA 
plus PMDP (M). In the case of the combined 
treatment with ds RNA plus PMDP, PMDP (6 mg/kg) 
significantly increase (70-80% protection) the an- 
tiviral activity of ds RNA. 
Protection of the ds RNA plus PMDP-treated 
mice depended on the challenge dose of the virus 
(fig.lA). These animals were fully protected up to 
a viral dose of 100 LD~o, but increasing the dose to 
>500 LDSO led to a decrease in the extent of pro- 
tection. Besides this, PMDP-induced enhancement 
in antiviral activity of ds RNA was also influenced 
by the day of PMDP administration (fig.lB). The 
animals that received the PMDP treatment be- 
10,000 
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tween day -9 and +2 were effectively protected 
against SFV infection. However this treatment was 
not effective if given on day + 9. No attempts were 
made to test the efficacy of the PMDP treatment 
beyond day + 9 or - 9. 
To determine whether the PMDP-induced in- 
crease in antiviral activity of ds RNA is due to an 
increased production of interferon, we measured 
the interferon titres in serum of mice treated with 
ds RNA, PMDP or ds RNA plus PMDP. Fig.2 
shows that PMDP alone did not induce interferon 
production, nor did it influence the kinetics of in- 
terferon synthesis in ds RNA-treated animals. This 
demonstrates that PMDP is neither an interferon 
inducer nor an activator of the interferon-inducing 
ability of ds RNA. It may, therefore, be inferred 
that the observed enhanced efficacy of the ds RNA 
plus PMDP treatment against SFV infection is not 
due to an increased production of interferon, but 
seems to result from a PMDP-induced stimulation 
of some specific and/or nonspecific immune 
response in the animals. That this indeed is the case 
was supported by our finding that mice treated 
with PMDP alone resist infection (table 2). Also, 
the PMDP-treated animals that survived the 
primary challenge with 2 LD5o of SFV developed 
sufficient immunity to resist strongly further 
challenge with higher doses of the virus (table 3). 
These findings are quite consistent with earlier 
studies which showed that MDP and its derivatives 
enhance nonspecific resistance to a variety of 
Table 2 
Effect of PMDP alone on SFV infection in mice 
Virus PMDP N Protec- P 
dose dose tion 
(LDso) (mglkg) (To) 
2 0 15 30 - 
0.6 15 30 - 
1.5 15 53 - 
3.0 15 80 co.01 
6.0 15 93 co.01 
12.0 15 73 - 
10 0 10 0 - 
6.0 10 10 - 
12.0 10 0 - 
PMDP was administered on day 0. N, number of mice 
40 
Table 3 
Rechallenge of mice which recovered from primary 
challenge with SFV 
Animal group Rechal- N Protec- p 
lenge dose tion 
(LDso) (%) 
PBS-treated 10 11 18 - 
PMDP-treated 10 28 57 co.05 
Control 10 10 10 - 
PBS-treated 100 9 0 - 
PMDP-treated 100 26 50 co.05 
Control 100 10 0 - 
PBS- and PMDP-treated animal groups were those 
surviving mice which were treated separately on day 0 
with PBS and PMDP (6 mg/kg), respectively, at the 
time of primary challenge (2 LD~o), while the control 
group consisted of normal mice which had never been 
infected. N, number of animals 
pathogens [3-61. As MDP and related glycopep- 
tides have been shown to activate macropohages 
[1,2,4], we propose that possible activation of 
these cells by PMDP may increase the efficacy of 
ds RNA-induced interferon response by control- 
ling the replication and/or spread of the virus. 
The present study demonstrates that the an- 
tiviral activity of an interferon inducer is con- 
siderably enhanced by PMDP. Since several non- 
pyrogenic but highly potent MDP derivatives [2], 
including PMDP (unpublished), are now available, 
a combined treatment with muramyl dipeptide and 
an interferon inducer offers a new possibility for 
the effective control of viral infections. 
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